

Instillo Group, Überherrn

"Nano- und Mikropartikel an der Schnittstelle zwischen Pharma und angrenzenden Bereichen

>20 Years of experience with Particles and Microreactors



2010 1996 2000 2011 2013 2014 **Quasaar GmbH MJR-Reactor Patent** leon nanodrugs GmbH QC and GMP Development **Synthesechemie** Services Nanopharmaceuticals Production of BaSO₄ Particles with 15-20 nm Size nanoSaar Lab nanoSaar AG **Synthesechemie**

Development of

MicroJet Reactor

by Dr. Penth

Instillo GmbH

Technology Development and Exploitation of MJR

Development Non-pharmaceuticals

MJR PharmJet GmbH

Transfer of operational business from Instillo

GmbH

New company site at Überherrn

Instillo Group

- > >40 employees at Überherrn
- >10 employees at Munich
- 3 employess at Starnberg




- 12000 m² total area; 5000 m² premises
- 350 m² offices; 1000 m² laboratories (expandable)
- 500 m³ ICH-stability storage (expandable to 2000m³)



Unique features of Particles with Microreactors






04.03.16

All around particles





From Lab Scale to Production Scale









Micro Reactor for Small Scale Production (GMP)



Nanoformulations from R&D to GMP

Challenges to overcome:

- Particle range defined in regulatory guidelines (>100 μ m, absence of particles >10 μ m) does not cover state-of the-art particle technology (10 nm 1000 nm)
- Not all relevant methods / equipment for characterization of nanoparticles are established in GMP
- Thoroughly characterization of particles are important, because of great impact of particle characteristics on drug product performance, bioavailability and efficacy
- Need for own validation and qualification concepts or development of dedicated equipment!
- Long-term stability effects of particles must be evaluated (agglomeration, disintegration, leakage effects...)
- Toxicological effects of particles must be investigated / defin










Combined therapy for Glioblastoma



SPION can be used simultaneously

- As drug delivery vehicle
 - = > Moved by magnetic forces
- Control of particles at tumor side
- For Hyperthermia therapy
- Combination of several therapies increases the patient compliance



Complex structure of SPION needed

Coating of SPION

- Using various polyanions or rather polycations
- Using various silans
- Molecular imprinting

Functionalization of SPION

- Disintegration of polymeric cover
 - pH-dependent
 - Temperature- dependent

Transfer of therapeutic particles to diagnostics



In-vitro diagnostics with magnetic nanoparticles

Ferrofluid



Nanoferrit



Advantage of magnetic nanoparticles

- Easy visualisation by MRT or EM
- Moving of particles in magnetic field (lab on a chip)
- Easy separation of particles by magnetic field
- Easy quantification of bound substrate by Magnet-Relaxometry

Advantage of Microreactor method

- High volume production of controlled particle size
- Coating with various surface agents possible
- Functionalisation of surface with various molecules possible

04.03.16

Drug eluting stents with nanoparticles



Advantage of polymeric nanoparticles

- Homogenous coating of stents
- Extended release of API
- Controlled application of API
- Optimal API dosing
- Enhanced stability

Advantage of Microreactor method

High API loading into polymeric systems

• Homogenous release through homogenous particle size





Contact:

Dr. Bernd Baumstümmler General Manager

Instillo GmbH

Comotorstr. 2

66802 Überherrn

Germany

Phone: +49-6836-9691100

E-Mail: b.baumstuemmler@instillo.de

Web: www.instillo.de